Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, has received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration. Jinsai Pharmaceutical’s domestic registration clinical trial application for GenSci141 ointment has been approved. GenSci141 ointment is a testosterone dihydrogel developed by Jinsai Pharmaceutical, classified as chemical drug categories 2.2 and 2.4.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Changchun High-tech: Subsidiary GenSci141 ointment domestic drug registration clinical trial application approved
Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, has received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration. Jinsai Pharmaceutical’s domestic registration clinical trial application for GenSci141 ointment has been approved. GenSci141 ointment is a testosterone dihydrogel developed by Jinsai Pharmaceutical, classified as chemical drug categories 2.2 and 2.4.